Association of cyclooxygenase-2 immunoreactivity with tumor recurrence and disease progression in superficial urothelial bladder cancer

Tumori

Volumn 92, Issue 2, 2006, Pages 124-129

  Mokos, Ivica ^a   Jakić Razumović, Jasminka ^a   Mareković, Zvonimir ^a   Pasini, Josip ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Bladder neoplasms; Disease progression; Local tumor recurrence; Prostaglandin endoperoxide synthase; Urothelium

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN SYNTHASE; TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; STROMA CELL; TRANSURETHRAL RESECTION; TUMOR RECURRENCE; UROGENITAL TRACT TUMOR; ADULT; AGED; BLADDER TUMOR; CARCINOMA; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; TIME; UROTHELIUM;

ADULT; AGED; CARCINOMA; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33744746520     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200207     Document Type: Article

References (40)

1. Calvel J, Cordier S, Boccon-Gibod L, Hemon D: Tobacco and bladder cancers in males: Increased risk for inhalers and smokers of black tobacco. Int J Cancer, 44: 605-610, 1989.
2. Greene FL, Page DL, Balch CM, Fleming ID, Morrow M: AJCC cancer staging manual. Springer Verlag, New York, 2002.
3. Bostwick DG, Mikuz G: Urothelial papillary (exophytic) neoplasms. Virchows Arch, 441: 109-116, 2002.
4. Oosterlinck W, Lobel B, Jakse G, Malström PU, Stöckle M, Sternberg C: Guidelines on bladder cancer. Eur Urol, 41: 105-112, 2002.
5. Stein JP, Grossfeld GD, Ginsberg DA, Ersig D, Freeman JA, Figueroa AJ, Skinner DG, Cote RJ: Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol, 160: 645-659, 1998.
6. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP: MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer, 88: 2598-2605, 2000.
7. De Vere-White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA Jr, Schellhammer PT, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED: The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. Eur Urol, 37: 595-600, 2000.
8. Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N, Miki T: Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer, 92: 510-518, 2001.
9. Gontero P, Casetta G, Zitella A, Ballario R, Paccioni D, Magnani C, Muir GH, Tizzani A: Evaluation of p53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumor recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol, 38: 287-296, 2000.
10. Kamai T, Takagi K, Asami H, Ito Y, Oshima H, Yoshida KI: Decreasing of p27 (Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer, 84: 1242-1251, 2001.
11. Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, De Gaetani C, Capeli G, Cittadini A, Trentini GP: Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer, 97: 671-678, 2002.
12. Leissner J, Hohenfellner R, Thüroff JW, Koppen C, Wolf HK: Prognostic significance of histopathological grading and immunoreactivity for p53 and p21/WAF1 in grade 2 pTa transitional cell carcinoma of the urinary bladder. Eur Urol, 39: 438-445, 2001.
13. Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami HO, Hacker DG, Hover R, Fraumeni JF Jr: Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst, 85: 307-311, 1993.
14. Suh O, Mettlin C, Petrelli NJ: Aspirin use, cancer and polyps of the large bowel. Cancer, 72: 1171-1177, 1993.
15. Trifan OC, Hla T: Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med, 7: 207-222, 2003.
16. Wendum D, Masliah J, Trugman G, Flejon JF: Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch, 445: 327-333, 2004.
17. Tsuji M, DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell, 83: 493-501, 1995.
18. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature, 359: 843-845, 1992.
19. Yan SF, Tritto I, Pinsky D, Liao H, Huang J, Fuller G, Brett J, May J, Stern D: Induction of interleukin 6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. J Biol Chem, 270: 11463-11471, 1995.
20. Karakurum M, Shreeniwas R, Chen J, Pinsky D, Yan SD, Anderson M, Sunouchi K, Major J, Hamilton T, Kuwabara K: Hypoxie induction of interleukin-8 gene expression in human endothelial cells. J Clin Invest, 93: 1564-1570, 1994.
21. Grubbs CJ, Lubet RA, Koki AT, Laehi KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K: Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)- nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res, 60: 5599-5602, 2000.
22. Okajima E, Uemura H, Ohnishi S, Tanaka M, Ohta M, Tani M, Fujimoto K, Ozono S, Okajima E, Hirao Y: Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection. Aktuelle Urol, 34: 256-258, 2003.
23. Mohseni H, Zaslau S, McFadden D, Riggs DR, Jackson BJ, Kandzari S: COX-2 inhibition demonstrates potent anti-proliferative effects on bladder cancer in vitro. Surg Res, 15: 138-142, 2004.
24. Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, Koch MO, Shappell SB, Breyer MD: Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol, 157: 29-35, 2000.
25. Ristimaki A, Nieminen O, Saukkonen K, Hotakinen K, Nordling S, Haglund C: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol, 158: 849-853, 2001.
26. Shirahama T: Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res, 6: 2424-2430, 2000.
27. Friedrich MG, Toma MI, Petri S, Huland H: Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence. BJU Int, 92: 389-392, 2003.
28. Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP: Cyclooxygenase-2 is highly expressed in carcinoma in situ and Tl transitional cell carcinoma of the bladder. J Urol, 169: 938-942, 2003.
29. Shinka T, Matsumoto M, Ogura H, Hirano A, Ohkawa T: Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guerin: a long term follow-up. Int J Urol, 4: 139-143, 1997.
30. Mulders PF, van der Meijden AP, Doesburg WH, Oosterhof GO, Debruyne FM: Prognostic factors in pTa-pT1 superficial bladder tumors treated with intravesical instillations. Br J Urol, 73: 403-408, 1994.
31. Kiemeney LALM, Witjes JA, Heijbroeck RP, Koper NP, Verbeek AL, Debruyne FM: Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Br J Urol, 73: 164-171, 1994.
32. Millan-Rodriguez F, Checile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J: Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol, 163: 73-78, 2000.
33. Mostofi FK, Sobin LH, Tosoni I: Histological typing of urinary bladder tumors. International classification of tumors, No 19. World Health Organization, Geneva, 1973.
34. Khan NM, Knapp DW, Denicola DB, Harris RK: Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res, 61: 478-481, 2000.
35. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT: Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res, 59: 5647-5650, 1999.
36. Pannone G, Bufo P, Caiaffa MF, Serpico R, Lanza A, Lo Muzio L, Rubini C, Staibano S, Petruzzi M, De Benedictis M, Tursi A, De Rosa G, Macchia L: Cyclooxygenase-2 expression in oral squamous carcinoma. Int J Immunopathol Pharmacol, 17: 273-282, 2004.
37. Kim SI, Kwon SM, Kim YS, Hong SJ: Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology, 60: 816-821, 2002.
38. Shariat SF, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner SP: Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of bladder. J Urol, 170: 985-989, 2003.
39. Wülfing C, Eltze E, von Struensee D, Wülfing P, Hertle L, Piechota H: Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol, 45: 46-52, 2004.
40. Wheeler MA, Hausladen DA, Yoon JH, Weiss RM: Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. J Urol, 168: 1568-1573, 2002.